New Born Screening at Dr. Essa Lab

New Born Screening at Dr. Essa Lab

New Born Screening is a comprehensive, highly specialized preventive healthcare program designed to identify congenital, metabolic, endocrine, and genetic disorders in newborn infants shortly after birth. This essential diagnostic panel is performed during the critical first few days of life, typically between 24 and 72 hours after birth. The primary clinical objective of New Born Screening at Dr. Essa Lab is to detect serious, potentially life-threatening conditions before clinical symptoms manifest. Many infants born with these inherited disorders appear perfectly healthy at birth, yet they lack specific enzymes or hormones required to process nutrients or maintain normal physiological functions. If left undetected and untreated, these conditions can lead to irreversible intellectual disabilities, severe physical developmental delays, organ damage, metabolic crises, or even premature death. By identifying these disorders in their pre-symptomatic phase, healthcare providers can initiate immediate medical interventions, dietary modifications, or hormone replacement therapies, ensuring the child can lead a healthy, normal life.

At Dr. Essa Lab, the New Born Screening panel utilizes advanced laboratory technologies, including Tandem Mass Spectrometry (MS/MS), Enzyme-Linked Immunosorbent Assay (ELISA), and molecular diagnostic techniques. These state-of-the-art methodologies allow for the highly sensitive and specific analysis of multiple biomarkers from a single, minimally invasive sample. The screening primarily evaluates metabolic pathways involving amino acids, organic acids, and fatty acid oxidation, alongside endocrine markers and red blood cell enzymes. The anatomical and physiological systems evaluated during this screening are vast, encompassing the thyroid gland, adrenal glands, liver, pancreas, hematological system, and cellular metabolic machinery. The clinical value of this test is unparalleled, serving as a cornerstone of preventive pediatrics. It empowers parents and pediatricians with actionable diagnostic data, transforming the clinical trajectory of congenital disorders from devastating illnesses to highly manageable conditions through early, targeted therapeutic strategies.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the clinical accuracy of the New Born Screening panel. Parents should adhere to the following medical guidelines before the sample collection:

• Timing of the Test: The sample must be collected after the first 24 hours of life but ideally before 72 hours. Samples collected before 24 hours of life may yield false-negative results for metabolic conditions like Phenylketonuria (PKU), as the infant must ingest sufficient breast milk or formula to allow metabolic byproducts to accumulate in the bloodstream.
• Feeding Requirements: The infant should be feeding normally (either breast milk or infant formula) for at least 24 hours prior to the test to ensure metabolic pathways are active and evaluable.
• Medical History Documentation: Inform the laboratory specialist if the infant has received any blood transfusions, total parenteral nutrition (TPN), or corticosteroid medications, as these can significantly alter endocrine and hematological screening parameters.
• Hydration and Warmth: Ensure the infant is well-hydrated and kept warm prior to the procedure. Warmth increases peripheral blood circulation, particularly in the heel, facilitating a smoother and quicker sample collection process.

During the Procedure

The sample collection for New Born Screening at Dr. Essa Lab is performed by highly trained pediatric phlebotomists who specialize in neonatal care, ensuring maximum safety, comfort, and precision:

• Infant Positioning: The infant is held securely by a parent or nurse, or placed comfortably on a changing table. The foot is positioned lower than the infant’s heart to encourage natural blood flow to the lower extremity.
• Heel Warming: A gentle, warm compress is applied to the infant’s heel for approximately 3 to 5 minutes. This vasodilates the local capillaries, ensuring an adequate blood flow and minimizing the need for multiple punctures.
• Aseptic Technique: The lateral or medial plantar surface of the heel is thoroughly cleansed with an antiseptic swab and allowed to air dry completely to prevent hemolysis of the sample or contamination with alcohol.
• The Puncture: A sterile, automated, single-use neonatal lancet designed specifically for heel pricks is used to make a shallow, precise incision. This device is engineered to avoid contact with the calcaneus (heel bone), eliminating any risk of osteomyelitis.
• Sample Collection: The first drop of blood is gently wiped away with sterile gauze to eliminate tissue fluids. Subsequent drops of blood are allowed to flow naturally and are applied directly to the designated circles on a specialized Guthrie filter paper card. Each circle must be completely saturated with a single, uniform drop of blood that penetrates through to the back of the card.
• Post-Procedure Care: Gentle pressure is applied to the puncture site with sterile gauze until hemostasis is achieved, and a small, hypoallergenic adhesive bandage is applied. The entire process takes approximately 10 to 15 minutes, with minimal discomfort to the newborn.

When is a New Born Screening Performed?

Routine Postnatal Assessment

New Born Screening is recommended as a routine, universal screening test for every single infant within the first few days of life. Pediatric guidelines globally mandate this screening because congenital and metabolic disorders are often clinically silent at birth. An infant may appear completely healthy, feed well, and have normal APGAR scores, yet harbor an underlying metabolic defect that will only manifest once irreversible neurological or physical damage has already occurred. Routine screening ensures that no child is left vulnerable to preventable developmental delays.

Family History of Genetic or Metabolic Disorders

Physicians urgently request a comprehensive New Born Screening when there is a documented family history of genetic mutations, metabolic syndromes, or unexplained infant mortality. In regions with high rates of consanguineous marriages, the risk of autosomal recessive disorders—such as Congenital Adrenal Hyperplasia, Phenylketonuria, or Maple Syrup Urine Disease—is significantly elevated. In these cases, the screening acts as a vital diagnostic safeguard to confirm or rule out inherited genetic anomalies immediately after birth.

Prevention of Unexplained Developmental Delay

The primary clinical indication for this screening is the prevention of profound, irreversible intellectual and physical disabilities. Conditions like Congenital Hypothyroidism or Phenylketonuria directly impair brain development and myelination in early infancy. If these conditions are not identified and treated within the first two to three weeks of life, the infant’s cognitive potential is permanently compromised. Screening allows for early intervention, preserving the child’s neurological and cognitive development.

Early Detection of Congenital Hypothyroidism

Congenital Hypothyroidism is one of the most common preventable causes of intellectual disability worldwide. It occurs when an infant is born without a fully functioning thyroid gland, leading to a severe deficiency of thyroid hormones. Because thyroid hormones are critical for early brain development and skeletal growth, pediatricians rely on New Born Screening to detect elevated Thyroid Stimulating Hormone (TSH) levels immediately, allowing for prompt thyroid hormone replacement therapy.

Screening for Metabolic Crises and Poor Feeding

Infants who present with acute, unexplained symptoms shortly after birth—such as extreme lethargy, poor feeding, persistent vomiting, hypotonia (floppiness), seizures, or a distinct sweet odor in their urine—may be experiencing a life-threatening metabolic crisis. These symptoms occur when the infant’s body cannot metabolize specific amino acids or organic acids, leading to a toxic accumulation of ammonia or ketones. New Born Screening rapidly identifies the underlying enzymatic defect, guiding immediate emergency dietary and medical management.

What Does a New Born Screening Detect?

The New Born Screening panel at Dr. Essa Lab is designed to detect a wide array of clinically significant congenital, endocrine, and metabolic disorders. The screening accurately identifies:

• Congenital Hypothyroidism (CH): A deficiency of thyroid hormone that leads to severe growth failure and intellectual disability if untreated.
• Congenital Adrenal Hyperplasia (CAH): A group of autosomal recessive disorders characterized by enzyme deficiencies in the adrenal steroidogenesis pathway, leading to salt-wasting crises and ambiguous genitalia.
• Phenylketonuria (PKU): An inability to metabolize the amino acid phenylalanine, leading to toxic accumulation in the brain and severe cognitive impairment.
• Galactosemia: A deficiency in the enzyme needed to convert galactose (milk sugar) into glucose, causing liver failure, cataracts, and mental retardation upon milk ingestion.
• Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: An enzyme deficiency that renders red blood cells susceptible to hemolysis under oxidative stress, leading to neonatal jaundice and hemolytic anemia.
• Cystic Fibrosis (CF): A genetic disorder affecting the exocrine glands, leading to abnormally thick mucus production, chronic pulmonary infections, and pancreatic insufficiency.
• Maple Syrup Urine Disease (MSUD): A metabolic disorder characterized by the inability to break down branched-chain amino acids, leading to rapid neurological deterioration and a sweet odor in urine.
• Biotinidase Deficiency: An enzyme deficiency that prevents the body from recycling biotin, leading to seizures, skin rashes, hair loss, and developmental delays.
• Sickle Cell Disease (SCD): An inherited red blood cell disorder that causes hemoglobin to form abnormal sickle shapes, leading to chronic anemia, painful vaso-occlusive crises, and organ damage.
• Beta Thalassemia Major: A severe genetic blood disorder characterized by reduced or absent synthesis of beta-globin chains, leading to profound hemolytic anemia.
• Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: A fatty acid oxidation disorder that prevents the body from breaking down fats for energy during periods of fasting, leading to severe hypoglycemia and lethargy.
• Homocystinuria: A metabolic disorder involving the amino acid methionine, leading to skeletal abnormalities, cardiovascular disease, and intellectual disability.
• Tyrosinemia Type I: A severe metabolic disorder caused by the lack of an enzyme needed to metabolize tyrosine, leading to progressive liver and kidney failure.
• Isovaleric Acidemia (IVA): An organic acid disorder characterized by a deficiency in isovaleryl-CoA dehydrogenase, leading to metabolic acidosis and a characteristic “sweaty feet” odor.
• Methylmalonic Acidemia (MMA): An organic acidemia that impairs the body’s ability to process certain proteins and fats, resulting in toxic accumulations and developmental delays.
• Propionic Acidemia: A metabolic disorder caused by a deficiency of propionyl-CoA carboxylase, leading to severe metabolic acidosis, hyperammonemia, and neurological damage.
• Glutaric Aciduria Type I: An inherited disorder where the body cannot break down certain amino acids, leading to an accumulation of toxic byproducts that damage the basal ganglia in the brain.
• Carnitine Uptake Deficiency: A condition that prevents the body from utilizing fats for energy, leading to cardiomyopathy, skeletal muscle weakness, and hypoglycemic encephalopathy.
• Citrullinemia: A urea cycle disorder that causes ammonia to accumulate rapidly in the blood, leading to cerebral edema, lethargy, and seizures.
• Argininosuccinic Aciduria: Another urea cycle defect resulting in hyperammonemia, liver enlargement, and progressive neurological impairment.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to delivering highly accurate diagnostic results with clinical efficiency, recognizing that early detection is paramount in neonatal care. The turnaround time for a comprehensive New Born Screening panel typically ranges from 5 to 7 working days. This timeframe is necessary to accommodate the complex, multi-step analytical processes involved in Tandem Mass Spectrometry (MS/MS) and ELISA testing, alongside rigorous quality control protocols overseen by consultant pathologists.

Once the analysis is complete, reports are thoroughly reviewed and signed off by a Consultant Pathologist specializing in metabolic and genetic testing. Parents can access the diagnostic reports conveniently through multiple digital channels. Reports are available for download via the official Dr. Essa Lab website portal and the dedicated mobile application. Additionally, automated notifications are sent via SMS, and reports can be received directly on WhatsApp. For families who prefer physical copies, reports can be collected from any of the numerous Dr. Essa Lab collection centers located across Karachi and other major cities.

New Born Screening Findings Overview

The following table outlines the key metabolic, endocrine, and genetic parameters evaluated during the New Born Screening panel, along with their clinical significance:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Thyroid Stimulating Hormone (TSH)	Normal TSH levels (indicates healthy thyroid function)	Elevated TSH (suggestive of Congenital Hypothyroidism)
Phenylalanine (Phe)	Normal phenylalanine concentrations in blood	Elevated Phenylalanine (suggestive of Phenylketonuria)
17-Hydroxyprogesterone (17-OHP)	Normal 17-OHP levels adjusted for gestational age	Elevated 17-OHP (suggestive of Congenital Adrenal Hyperplasia)
Galactose-1-Phosphate (GALT)	Normal GALT enzyme activity	Decreased or absent GALT activity (suggestive of Galactosemia)
Glucose-6-Phosphate Dehydrogenase (G6PD)	Normal G6PD enzyme activity in red blood cells	Deficient G6PD enzyme activity (suggestive of G6PD Deficiency)
Immunoreactive Trypsinogen (IRT)	Normal IRT levels	Significantly elevated IRT (suggestive of Cystic Fibrosis)
Biotinidase Activity	Normal biotinidase enzyme function	Partial or complete absence of Biotinidase (Biotinidase Deficiency)
Hemoglobin Electrophoresis / HPLC	Normal adult and fetal hemoglobin patterns (HbF and HbA)	Presence of HbS, HbC, or abnormal ratios (Sickle Cell / Thalassemia)
Acylcarnitine Profile (MS/MS)	Normal fatty acid and organic acid metabolic profiles	Elevated specific acylcarnitines (suggestive of Fatty Acid Oxidation defects)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for New Born Screening?

• Established Diagnostic Excellence: Dr. Essa Lab has been a trusted name in diagnostic pathology and radiology since 1987, offering decades of clinical expertise.
• ISO 15189 Certified Laboratories: Our laboratories adhere to strict international quality management standards, ensuring the highest level of diagnostic accuracy and reliability.
• Advanced Tandem Mass Spectrometry (MS/MS): We utilize cutting-edge analytical technology to screen for dozens of metabolic disorders from a single dried blood spot.
• Expert Pediatric Pathologists: All neonatal and genetic reports are analyzed and interpreted by highly qualified consultant pathologists specializing in metabolic medicine.
• Convenient Home Sample Collection: To protect the delicate health of your newborn, Dr. Essa Lab offers professional, sterile home sample collection services across Karachi.
• Rapid and Secure Digital Report Access: Parents can easily access, download, and share reports via our website, mobile app, or WhatsApp.
• Compassionate Neonatal Care: Our phlebotomists are specially trained in pediatric and neonatal sample collection, ensuring a gentle, safe, and stress-free experience for your baby.
• Extensive Network: With numerous branches across Karachi and Pakistan, accessing high-quality diagnostic services is always convenient and accessible.